American Headache Society (AHS) 2020 Virtual Annual Scientific Meeting

Eptinezumab improves outcomes, lowers medication use in patients with chronic migraine and medication-overuse headache

Roshini Claire Anthony, 20200821200001

In patients diagnosed with chronic migraine and medication-overuse headache (MOH), treatment with eptinezumab led to improved patient-reported outcomes, fewer migraine days, and a reduction in acute medication use, according to subgroup analyses of the PROMISE-2* trial presented at AHS 2020.

Sustained reduction in chronic migraine with onabotulinumtoxinA

Roshini Claire Anthony, 20200731140001

Continuous onabotulinumtoxinA treatment led to a sustained reduction in chronic migraine, according to pooled analysis of the double-blind and open-label phases of the PREEMPT* trial.

Rimegepant yields rapid, sustained pain relief for acute migraine

Pearl Toh, 20200721190000

A single oral dose of rimegepant offers rapid, sustained pain relief for the acute treatment of migraine, thus allowing early return to normal function without the need for repeat dosing or rescue medications, results of three phase III studies presented at the AHS 2020 Meeting have shown.

Low incidence of CV AEs with lasmiditan in migraine

Roshini Claire Anthony, 20200720140001

Cardiovascular (CV) event incidence was low among patients taking lasmiditan for migraine, according to interim analysis of the phase III GLADIATOR* study presented at AHS 2020.

Riboflavin may help reduce frequency of paediatric migraine

Elaine Soliven, 20200720000000

Treatment with riboflavin significantly reduced monthly headache days in children and adolescents with migraine, according to a study presented at AHS 2020.

Subgroup findings boost ubrogepant benefit for migraine

Audrey Abella, 20200717100000

Ubrogepant sustains its favourable effect for migraine regardless of demographic and clinical features, and concomitant medication use, according to pooled results of the ACHIEVE I and II studies presented at AHS 2020.

Galcanezumab may CONQUER treatment-resistant migraine

Audrey Abella, 20200714100000

The monoclonal antibody galcanezumab may deliver benefit for treatment-resistant* episodic or chronic migraine, according to post hoc results of the CONQUER trial presented at AHS 2020.

DFN-15 may be effective in relieving migraine

Elaine Soliven, 20200714000000

Treatment with DFN-15 may effectively alleviate pain and the most bothersome symptoms in adults with episodic migraine, according to two phase III studies presented at AHS 2020.

OnabotulinumtoxinA effectively controls chronic migraine

Audrey Abella, 20200708100000

Long-term use of onabotulinumtoxinA led to reductions in monthly headache days (MHDs) in adults with chronic migraine (CM), according to post hoc analyses of the COMPEL* study presented at the AHS 2020 virtual scientific meeting.

$Fremanezumab: Sustained benefits across the board for refractory migraine$

Fremanezumab: Sustained benefits across the board for refractory migraine

Pearl Toh, 20200703182000

After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.